Quell Therapeutics Limited
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Quell Therapeutics Limited
Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.
AstraZeneca has maintained sector-beating growth for five years, but is looking to a new wave of bolt-on acquisitions and licensing deals to sustain that trajectory beyond 2030.
Eisai and Lilly were the biggest winners at the 19th Annual Scrip Awards in a glittering ceremony at the Dorchester in London’s Mayfair, hosted by the actor and comedian Jon Culshaw.
The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001, which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."
- Gene Therapy, Cell Therapy
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.